{"groups":[{"description":"Participants received fluoropyrimidine (EITHER 5-fluorouracil \\[5-FU\\] or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles as follows: cisplatin 80 milligrams per square meter (mg/m\\^2), intravenously (IV), on Day 1 and EITHER: 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2 tablets, orally (PO), twice daily (BID) from the evening of Day 1 through the morning of Day 15.","id":"FG000","title":"Fluoropyrimidine/Cisplatin (FP)"},{"description":"Participants received trastuzumab plus fluoropyrimidine (EITHER 5-FU or capecitabine, at the investigator's discretion) and cisplatin once every 3 weeks (one cycle) for a maximum of 6 cycles (except as noted) as follows: trastuzumab 8 milligrams per kilogram (mg/kg), IV, on Day 1 (Cycle 1), followed by 6 mg/kg, IV (Cycles 2 onward, administered until disease progression); cisplatin 80 mg/m\\^2 IV on Day 1; and EITHER 5-FU 800 mg/m\\^2 continuous IV infusion on Days 1 through 5 OR capecitabine 1000 mg/m\\^2 tablets, PO BID from the evening of Day 1 through the morning of Day 15.","id":"FG001","title":"Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"35"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"200"},{"groupId":"FG001","numSubjects":"210"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Violation of Selection Criteria"},{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"29"},{"groupId":"FG001","numSubjects":"23"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}],"type":"Failure to Return"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"23"}],"type":"Other"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"290"},{"groupId":"FG001","numSubjects":"294"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"251"},{"groupId":"FG001","numSubjects":"251"}],"type":"Entered Follow-Up"},{"achievements":[{"groupId":"FG000","numSubjects":"199"},{"groupId":"FG001","numSubjects":"200"}],"type":"Died in Follow-up"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"10"}],"type":"Lost to Follow-up"},{"achievements":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"41"}],"type":"Alive in Follow-up"},{"achievements":[{"comment":"Summary of withdrawals represents withdrawals from treatment, rather than withdrawals from study.","groupId":"FG000","numSubjects":"0"},{"comment":"Summary of withdrawals represents withdrawals from treatment, rather than withdrawals from study.","groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"290"},{"groupId":"FG001","numSubjects":"294"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}